drugset / Trial / NCT07300735

Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers

NCT07300735

Recruiting 88 enrolled Alexandria University
RandomizedParallel-groupOpen-labelSupportive care

Summary

This is a comparative interventional study to determine the best way to prevent G-CSF induced bone pain in patients with hematological malignancies (blood cancers). G-CSF (Granulocyte Colony-Stimulating Factor) is a drug commonly used in these patients to boost white blood cell production, but it frequently causes severe bone pain. The study is comparing two oral medications for their effectiveness as a preventive treatment: * Diosmin-Hesperidin (a flavonoid supplement). * Loratadine (a common anti-allergy medication). The core question the study is trying to answer is: * Is diosmin-hesperidin effective in preventing G-CSF-induced bone pain compared to loratadine? * Does the combination of diosmin-hesperidin and loratadine offer better pain prevention than either drug alone?

Timeline

Start
2025-03-01
Primary completion
2027-03
Completion
2027-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Diosmin Small molecule 500 mg Oral
Subject Loratadine Small molecule 10 mg Oral